The independent source for health policy research, polling, and news.
181 - 200 of 466 Results
California and New York would be the first states to require anyone under 18 to obtain prescriptions to purchase over-the-counter weight loss products, which some research has linked to eating disorders.
With fears of a winter surge looming, government agencies have authorized and encouraged vaccination with a newly formulated booster. But the science to support that decision remains inconclusive.
Lori McClintock, the wife of U.S. Rep. Tom McClintock of California, died after ingesting white mulberry leaf, according to the Sacramento County coroner. The plant is generally considered safe and is used in herbal remedies that claim to lower blood sugar, boost weight loss, and combat high cholesterol. Her death highlights the potential dangers of dietary supplements.
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHNs Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when not if the old ones fail.
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHNs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the governments covid-fighting strategy.
The Supreme Courts decision overturning Roe v. Wade has created far more questions than it has answered about the continued legality and availability of abortion, as both abortion rights supporters and anti-abortion activists scramble to put their marks on policy. Meanwhile, Congress completes work on its gun bill and the FDA takes up the problem of the next covid-19 booster. Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of KHN join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNs Angela Hart, who reported and wrote the latest KHN-NPR Bill of the Month episode about two identical eye surgeries with very different price tags.
The FDA is using its power to regulate tobacco products ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNs Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
Approved as a device, not a drug, Plenity contains a plant-based gel that swells to fill 25% of a persons stomach, to help people eat less. Results vary widely but are modest on average.
As a Senate committee considered legislation to reauthorize the FDAs user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.
The wait is nearly over for parents of kids under 5 as a key advisory committee to the FDA recommends authorizing a covid-19 vaccine for the youngest children. Meanwhile, Congress is struggling to fill in the details of its gun control compromise, and, as the Supreme Court prepares to throw the question of abortion legality back to the states, the number of abortions has been rising. Shefali Luthra of The 19th, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KHNs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
One million Americans have died from covid-19 far more per capita than in any other developed country. A new variant is doubling case rates in some states, and more than 300 people are dying a day. But our nations pandemic response has become mild-mannered and performative, backed by neither money, urgency, nor enforcement.
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicares trustees board.
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nations most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
The Biden administration may have authority to allow the use of abortion pills even in states where the practice could be outlawed, say legal experts.
Two mass shootings in two weeks one at a Texas elementary school that killed 19 fourth graders and two teachers have reignited the guns-as-public-health-problem debate. But political consensus seems as far away as ever. Meanwhile, the FDA is in the congressional hot seat over its handling of the infant formula shortage. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Rachana Pradhan of KHN join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Richard Baron, head of the American Board of Internal Medicine, about how doctors should discipline colleagues who spread medical misinformation.
穢 2026 KFF